{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:18:18Z","timestamp":1781108298362,"version":"3.54.1"},"reference-count":42,"publisher":"National Academy of Sciences","issue":"14","content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2014,4,8]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>\n                    Isoniazid preventive therapy (IPT) is a key tuberculosis prevention strategy in high-HIV-prevalent settings. While randomized controlled trials have shown IPT provides protection against tuberculosis disease in HIV-positive patients during therapy, protection was quickly lost after cessation of therapy. It was not known whether this loss of protection is due to reinfection and rapid progression to disease, or lack of cure. Using mathematical modeling, fitted to trial data, we show IPT does not cure\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    infection in the majority of HIV-infected individuals. These results contrast with long-held beliefs about the working mechanism of IPT, but explain the empirical results. These results are important for determining appropriate clinical guidelines for IPT use in varying epidemiological settings.\n                  <\/jats:p>","DOI":"10.1073\/pnas.1317660111","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T01:25:24Z","timestamp":1395710724000},"page":"5325-5330","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":43,"title":["Ability of preventive therapy to cure latent\n                    <i>Mycobacterium tuberculosis<\/i>\n                    infection in HIV-infected individuals in high-burden settings"],"prefix":"10.1073","volume":"111","author":[{"given":"Rein M. G. J.","family":"Houben","sequence":"first","affiliation":[{"name":"TB Modelling Group, Department of Infectious Disease Epidemiology,"},{"name":"TB Centre, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Sumner","sequence":"additional","affiliation":[{"name":"TB Modelling Group, Department of Infectious Disease Epidemiology,"},{"name":"TB Centre, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison D.","family":"Grant","sequence":"additional","affiliation":[{"name":"TB Centre, and"},{"name":"Department of Clinical Research, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"White","sequence":"additional","affiliation":[{"name":"TB Modelling Group, Department of Infectious Disease Epidemiology,"},{"name":"TB Centre, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2014,3,24]]},"reference":[{"key":"e_1_3_3_1_2","volume-title":"Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings","author":"World Health Organization","year":"2011","unstructured":"; World Health Organization Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings (World Health Org, 2011)."},{"key":"e_1_3_3_2_2","first-page":"CD000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","author":"Akolo C","year":"2010","unstructured":"C Akolo, I Adetifa, S Shepperd, J Volmink, Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, pp. CD000171 (2010).","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_3_2","first-page":"895","article-title":"Tuberculin reactivity and the risk of tuberculosis: A review","volume":"4","author":"Watkins RE","year":"2000","unstructured":"RE Watkins, R Brennan, AJ Plant, Tuberculin reactivity and the risk of tuberculosis: A review. Int J Tuberc Lung Dis 4, 895\u2013903 (2000).","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200111090-00009"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199707000-00006"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005136"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60204-3"},{"key":"e_1_3_3_8_2","unstructured":"Samandari T et al. (2012) TB incidence increase after cessation of 36 months\u2019 isoniazid Prophylaxis in HIV. Conference on Retroviruses and Opportunistic Infections (abstr 147). Available at www.croi2014.org\/past_croi_conferences. Accessed June 1 2013."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214289"},{"key":"e_1_3_3_10_2","volume-title":"Epidemiology of Tuberculosis, Selected Papers","author":"Styblo K","year":"1991","unstructured":"K Styblo Epidemiology of Tuberculosis, Selected Papers (Royal Netherlands Tuberculosis Assoc, The Hague, 1991)."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1005660107"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/508206"},{"key":"e_1_3_3_13_2","volume-title":"Essential Medical Statistics","author":"Kirkwood BR","year":"2003","unstructured":"BR Kirkwood, JAC Sterne Essential Medical Statistics (Blackwell Science, 2nd Ed, Malden, MA, 2003).","edition":"2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-3-200808050-00241"},{"key":"e_1_3_3_15_2","first-page":"1192","article-title":"False-positive tuberculin skin tests: What is the absolute effect of BCG and non-tuberculous mycobacteria?","volume":"10","author":"Farhat M","year":"2006","unstructured":"M Farhat, C Greenaway, M Pai, D Menzies, False-positive tuberculin skin tests: What is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 10, 1192\u20131204 (2006).","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268897007917"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-3879(82)80013-5"},{"key":"e_1_3_3_18_2","first-page":"24","article-title":"HIV increases the risk of TB due to recent infection more than that due to reactivation of latent infection","volume":"15","author":"Houben RMGJ","year":"2011","unstructured":"RMGJ Houben, et al., HIV increases the risk of TB due to recent infection more than that due to reactivation of latent infection. Int J Tuberc Lung Dis 15, 24\u201331 (2011).","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_19_2","first-page":"909","article-title":"Human immunodeficiency virus increases the risk of tuberculosis due to recent re-infection in individuals with latent infection","volume":"14","author":"Houben RM","year":"2010","unstructured":"RM Houben, et al., Human immunodeficiency virus increases the risk of tuberculosis due to recent re-infection in individuals with latent infection. Int J Tuberc Lung Dis 14, 909\u2013915 (2010).","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832f51cf"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06712-5"},{"key":"e_1_3_3_22_2","unstructured":"R Core Team (2013) R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing Vienna)."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh021"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/431517"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1050(199906)8:4<323::AID-HEC431>3.0.CO;2-0"},{"key":"e_1_3_3_26_2","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock GW","year":"1999","unstructured":"GW Comstock, How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 3, 847\u2013850 (1999).","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_27_2","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: A final report of the bethel isoniazid studies","volume":"119","author":"Comstock GW","year":"1979","unstructured":"GW Comstock, C Baum, DE Snider, Isoniazid prophylaxis among Alaskan Eskimos: A final report of the bethel isoniazid studies. Am Rev Respir Dis 119, 827\u2013830 (1979).","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_3_28_2","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","unstructured":"; International Union Against Tuberculosis Committee on Prophylaxis, Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull World Health Organ 60, 555\u2013564 (1982).","journal-title":"Bull World Health Organ"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2011.12.013"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203636109"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200210-1125OC"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00079310"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000391011.40892.ff"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0962-8479(92)90087-Z"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016130"},{"key":"e_1_3_3_36_2","first-page":"810","article-title":"Anti-tuberculosis drug resistance surveillance in Uganda 1996\u20131997","volume":"3","author":"Bretzel G","year":"1999","unstructured":"G Bretzel, et al., Anti-tuberculosis drug resistance surveillance in Uganda 1996\u20131997. Int J Tuberc Lung Dis 3, 810\u2013815 (1999).","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070763"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1205.050681"},{"key":"e_1_3_3_39_2","unstructured":"Rangaka MX et al. (2012) Randomized controlled trial of isoniazid preventive therapy in HIV-infected persons on antiretroviral therapy. XIX International AIDS Conference (abstr THLBB03). Available at http:\/\/pag.aids2012.org\/Abstracts.aspx?SID=16&AID=21471. Accessed March 11 2014."},{"key":"e_1_3_3_40_2","volume-title":"Global HIV\/AIDS Response\u2014Epidemic update and health sector progress towards Universal Access\u2014Progress Report 2011","author":"UNAIDS","year":"2011","unstructured":"; UNAIDS Global HIV\/AIDS Response\u2014Epidemic update and health sector progress towards Universal Access\u2014Progress Report 2011 (World Health Org, Geneva, 2011)."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034156"},{"key":"e_1_3_3_42_2","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"; Centers for Disease Control and Prevention, Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 60, 1650\u20131653 (2011).","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1317660111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T23:13:01Z","timestamp":1649805181000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1317660111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,24]]},"references-count":42,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2014,4,8]]}},"alternative-id":["10.1073\/pnas.1317660111"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1317660111","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,24]]},"assertion":[{"value":"2014-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}